Platelets, also called thrombocytes (thromb- + -cyte, "blood clot cell"), are a component of blood whose function (along with the coagulation factors) is to stop bleeding by clumping and clotting blood vessel injuries. Platelets have no cell nucleus: they are fragments of cytoplasm that are derived from the megakaryocytes of the bone marrow, and then enter the circulation. These unactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 µm in greatest diameter. Platelets are found only in mammals, whereas in other animals (e.g. birds, amphibians) thrombocytes circulate as intact mononuclear cells.
On a stained blood smear, platelets appear as dark purple spots, about 20% the diameter of red blood cells. The smear is used to examine platelets for size, shape, qualitative number, and clumping. The ratio of platelets to red blood cells in a healthy adult is 1:10 to 1:20.
The main function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site of interrupted endothelium. They gather at the site and unless the interruption is physically too large, they plug the hole. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation. Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white clot" to a predominantly fibrin clot, or "red clot" or the more typical mixture. The final result is the clot. Some would add the subsequent clot retraction and platelet inhibition as fourth and fifth steps to the completion of the process and still others a sixth step wound repair.
Low platelet concentration is thrombocytopenia and is due to either decreased production or increased destruction. Elevated platelet concentration is thrombocytosis and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. A disorder of platelet function is a thrombocytopathy.
Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different than those of a normal clot: namely, extending the fibrin clot of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.
- 1 History
- 2 Measurement
- 3 Structure
- 4 Symptoms of platelet disorders
- 5 Kinetics
- 6 Dynamics
- 7 Adhesion
- 8 Activation
- 9 Aggregation
- 10 Wound repair
- 11 Platelet-coagulation factor interactions
- 12 Role in non-hematologic diseases
- 13 Clot formation in non-mammalian vertebrates
- 14 Tests of platelet function
- 15 Platelet disorders
- 16 Drugs affecting platelets
- 17 Therapy with platelets
- 18 References
- 19 Further reading
- 20 External links
George Gulliver in 1841 drew pictures of platelets using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister. This microscope improved resolution sufficiently to make it possible to see platelets for the first time. William Addison in 1842 drew pictures of a platelet-fibrin clot. Lionel Beale in 1864 was the first to publish a drawing showing platelets. Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material. Queen's College, Birmingham (a predecessor college of Birmingham University) physician Dr Richard Hill Norris was the first to describe the action of platelets in 1880. Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo. He named Schultz's spherules (It.) piastrine: little plates. William Osler observed them and, in published lectures in 1886, called them a third corpuscle and a blood plaque and described them as a colorless protoplasmic disc. James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication but changed to platelets in his 1910 publication which has become the universally accepted term.
The term thrombocyte (clot cell) came into use in the early 1900s and is sometimes used as a synonym for platelet; but not generally in the scientific literature, except as a root word for other terms related to platelets (e.g. thrombocytopenia meaning low platelets). Thrombocytes are cells found in the blood of non-mammalian vertebrates. They are the functional equivalents of platelets, but circulate as intact mononuclear cells, and are not simply cytoplasmic fragments of bone marrow megakaryocytes.
In some contexts, the word thrombus is used interchangeably with the word clot, regardless of its composition (white, red, or mixed). In other contexts it is used to contrast a normal from an abnormal clot: thrombus arises from physiologic hemostasis, thrombosis arises from a pathologic and excessive quantity of clot. In a third context it is used to contrast the result from the process: thrombus is the result, thrombosis is the process.
Platelet concentration is measured either manually using a hemocytometer, or by placing blood in an automated platelet analyzer using electrical impedance, such as a Coulter counter. The normal range (99% of population analyzed) for platelets in healthy Caucasians is 150,000 to 450,000 per cubic millimeter (a mm3 equals a microliter). or 150–400 × 109 per litre. The normal range has been confirmed to be the same in the elderly and Spanish populations.
Structurally the platelet can be divided into four zones, from peripheral to innermost:
- Peripheral zone - is rich in glycoproteins required for platelet adhesion, activation, and aggregation. For example, GPIb/IX/X; GPVI; GPIIb/IIIa.
- Sol-gel zone - is rich in microtubules and microfilaments, allowing the platelets to maintain their discoid shape.
- Organelle zone - is rich in platelet granules. Alpha granules contain clotting mediators such as factor V, factor VIII, fibrinogen, fibronectin, platelet-derived growth factor, and chemotactic agents. Delta granules, or dense bodies, contain ADP, calcium, serotonin, which are platelet-activating mediators.
- Membranous zone - contains membranes derived from megakaryocytic smooth endoplasmic reticulum organized into a dense tubular system which is responsible for thromboxane A2 synthesis. This dense tubular system is connected to the surface platelet membrane to aid thromboxane A2 release.
Symptoms of platelet disorders
Spontaneous and excessive bleeding can occur because of platelet disorders. This bleeding can be caused by deficient numbers of platelets, dysfunctional platelets, or very excessive numbers of platelets: over 1.0 million/microliter. (The excessive numbers create a relative von Willebrand factor deficiency due to sequestration.)
One can get a clue as to whether bleeding is due to a platelet disorder or a coagulation factor disorder by the characteristics and location of the bleeding. All of the following suggest platelet bleeding, not coagulation bleeding: the bleeding from a skin cut such as a razor nick is prompt and excessive, but can be controlled by pressure; spontaneous bleeding into the skin which causes a purplish stain named by its size: petechiae, purpura, ecchymoses; bleeding into mucous membranes causing bleeding gums, nose bleed, and gastrointestinal bleeding; menorrhagia; and intraretinal and intracranial bleeding.
- Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver.
- Each megakaryocyte produces between 1,000 and 3,000 platelets during its lifetime.
- An average of 1011 platelets are produced daily in a healthy adult.
- Reserve platelets are stored in the spleen, and are released when needed by splenic contraction induced by the sympathetic nervous system.
- The average life span of circulating platelets is 8 to 9 days. Life span of individual platelets is controlled by the internal apoptotic regulating pathway, which has a Bcl-xL timer.
- Old platelets are destroyed by phagocytosis in the spleen and liver.
An overview summarizing platelet dynamics, the complex process of converting inactive platelets into a platelet plug, is essentialEL 2. Complicating any verbal description is the fact that at least 193 proteins and 301 interactions are involved in platelet dynamics. The separation of platelet dynamics into three stages is useful in this regard, but it is artificial: in fact, each stage is initiated in rapid succession, and each continues until the trigger for that stage is no longer present, so there is overlap.
Endothelial cells are attached to the subendothelial collagen by von Willebrand factor (VWF) which these cells produce. VWF is also stored in the Weibel-Palade bodies of the endothelial cells and secreted constitutively into the blood. Platelets store vWF in their alpha granules.
When the endothelial layer is disrupted, collagen and VWF anchor platelets to the subendothelium. Platelet GP1b-IX-V receptor binds with VWF; and GPVI receptor and integrin alpha2beta1 bind with collagen.
An overview of platelet activation is a useful introduction to this multifaceted process. [EL 3]
Resting platelets maintain active calcium efflux via a cyclic AMP activated calcium pump. Intracellular calcium concentration determines platelet activation status, as it is the second messenger that drives platelet conformational change and degranulation (see below). Endothelial prostacyclin binds to prostanoid receptors on the surface of resting platelets. This event stimulates the coupled Gs protein to increase adenylate cyclase activity and increases the production of cAMP, further promoting the efflux of calcium and reducing intracellular calcium availability for platelet activation.
ADP on the other hand binds to purinergic receptors on platelet surface. Since the thrombocytic purinergic receptor P2Y12 is coupled to Gi proteins, ADP reduces platelet adenylate cyclase activity and cAMP production, leading to accumulation of calcium inside the platelet by inactivating the cAMP calcium efflux pump. The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 PLCB2, resulting in inositol 1,4,5-trisphosphate (IP3)generation and intracellular release of more calcium. This together induces platelet activation. Endothelial ADPase degrades ADP and prevents this from happening. Clopidogrel and related antiplatelet medications also work as purinergic receptor P2Y12 antagonists.
Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors on the platelet. GPVI is associated with the Fc receptor gamma chain and leads via the activation of a tyrosine kinase cascade finally to the activation of PLC-gamma2 PLCG2 and more calcium release.
Tissue factor also binds to factor VII in the blood, which initiates the extrinsic coagulation cascade to increase thrombin production. Thrombin is a potent platelet activator, acting through Gq and G12. These are G protein coupled receptors and they turn on calcium mediated signaling pathways within the platelet, overcoming the baseline calcium efflux. Families of three G proteins (Gq, Gi, G12) operate together for full activation. Thrombin also promotes secondary fibrin-reinforcement of the platelet plug. Platelet activation in turn degranulates and releases factor V and fibrinogen, potentiating the coagulation cascade. So in reality the process of platelet plugging and coagulation are occurring simultaneously rather than sequentially, with each inducing the other to form the final clot.
Collagen-mediated GPVI signalling increases the platelet production of thromboxane A2 (TXA2) and decreases the production of prostacyclin. This occurs by altering the metabolic flux of platelet's eicosanoid synthesis pathway, which involves enzymes phospholipase A2, cyclo-oxygenase 1, and thromboxane-A synthase. Platelets secrete thromboxane A2, which acts on the platelet's own thromboxane receptors on the platelet surface (hence the so-called "out-in" mechanism), and those of other platelets. These receptors trigger intraplatelet signaling, which converts GPIIb/IIIa receptors to their active form to initiate aggregation.
Platelets contain dense granules, lambda granules and alpha granules. Activated platelets secrete the contents of these granules through their canalicular systems to the exterior. Simplistically, bound and activated platelets degranulate to release platelet chemotactic agents to attract more platelets to the site of endothelial injury. Granule characteristics:
- α granules (alpha granules) – containing P-selectin, platelet factor 4, transforming growth factor-β1, platelet-derived growth factor, fibronectin, B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII).
- δ granules (delta or dense granules) – containing ADP or ATP, calcium, and serotonin).
- γ granules (gamma granules) – similar to lysosomes and contain several hydrolytic enzymes.
- λ granules (lambda granules) – contents involved in clot resorption during later stages of vessel repair.
Mitochondria hyperpolarization is a key event in initiating changes in morphology. Intraplatelet calcium concentration increases, stimulating the interplay between microtubule/actin filament complex. The continuous changes in shape from the unactivated to the fully activated platelet is best seen on scanning electron microscopy.[EL 4] Three steps along this path are named early dendritic, early spread and spread. The surface of the unactivated platelet looks very similar to the surface of the brain, with a wrinkled appearance from numerous shallow folds to increase the surface area; early dendritic, an octopus with multiple arms and legs; early spread, an uncooked frying egg in a pan, the "yolk" being the central body; and the spread, a cooked fried egg with a denser central body. These changes are all brought about by the interaction of the microtubule/actin complex with the platelet cell membrane and open canalicular system (OCS), which is an extension and invagination of that membrane. This complex runs just beneath these membranes, and is the chemical motor which literally pulls the invaginated OCS out of the interior of the platelet like turning pants pockets inside out, creating the dendrites.[EL 7] and then spreads each dendrite until the entire OCS becomes indistinguishable from the initial platelet membrane as it forms the "fried egg". This dramatic increase in surface area comes about with neither stretching nor adding phospholipids to the platelet membrane.
Platelet activation causes its membrane surface to become negatively charged. One of the signaling pathways turns on scramblase, which moves negatively charged phospholipids from the inner to the outer platelet membrane surface. These phospholipids then bind the tenase and prothrombinase complexes, two of the sites of interplay between platelets and the coagulation cascade. Calcium ions are essential for the binding of these coagulation factors.
Aggregation begins minutes after activation, and occurs as a result of turning on the GPIIb/IIIa receptor, allowing these receptors to bind with vWF or fibrinogen. There are 50–100 of these receptors per platelet. When any one or more of at least nine different platelet surface receptors are turned on during activation, intraplatelet signaling pathways cause existing GpIIb/IIIa receptors to change shape – curled to straight – and thus become capable of binding.
Since fibrinogen is a rod-like protein with nodules on either end capable of binding GPIIb/IIIa, activated platelets with exposed GPIIb/IIIa can bind fibrinogen to aggregate. GPIIb/IIIa may also further anchor the platelets to subendothelial vWF for additional clot structural stabilisation.
Classically it was thought that this was the only mechanism involved in aggregation, but three new mechanisms have been identified which can initiate aggregation, depending on the velocity of blood flow (i.e. shear range).
The blood clot is only a temporary solution to stop bleeding; tissue repair is needed. Small interruptions in the endothelium are handled by physiological mechanisms; large interruptions by the trauma surgeon.  The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis.
Platelet-coagulation factor interactions
In addition to interacting with vWF and fibrin, platelets interact with thrombin, Factors X, Va, VIIa, XI, IX, and prothrombin to complete clot formation via the coagulation cascade. Six studies suggested platelets express tissue factor: the definitive study shows they do not. The platelets from rats were conclusively shown to express tissue factor protein and also it was proved that the rat platelets carry both the tissue factor pre-mRNA and mature mRNA.
Role in non-hematologic diseases
In addition to being the cellular effector of hemostasis, platelets are rapidly deployed to sites of injury or infection, and potentially modulate inflammatory processes by interacting with leukocytes and by secreting cytokines, chemokines, and other inflammatory mediators. Platelets also secrete platelet-derived growth factor (PDGF).
Clot formation in non-mammalian vertebrates
Instead of having platelets, non-mammalian vertebrates have thrombocytes, which have a nucleus and resemble B lymphocytes in morphology. They aggregate in response to thrombin, but not to ADP, serotonin, nor adrenaline, as platelets do.
Tests of platelet function
Developed by Duke in 1910 and bearing his name, it measured the time for bleeding to stop from a standardized wound in the ear lobe which is blotted each 30 seconds. Normal was less than 3 minutes. More modern techniques are now used. A normal bleeding time reflects sufficient platelet numbers and function plus normal microvasculature.
Multiplate multiple electrode aggregometry
In the Multiplate analyzer, anticoagulated whole blood is mixed with saline and a platelet agonist in a single use cuvette with two pairs of electrodes. The increase in impedance between the electrodes as platelets aggregate onto them, is measured and visualized as a curve.
The PFA-100 is a system for analysing platelet function in which citrated whole blood is aspirated through a disposable cartridge containing an aperture within a membrane coated with either collagen and epinephrine or collagen and ADP. These agonists induce platelet adhesion, activation and aggregation leading to rapid occlusion of the aperture and cessation of blood flow termed the closure time (CT). An elevated CT with EPI and collagen can indicate intrinsic defects such as von Willebrand disease, uremia, or circulating platelet inhibitors. The follow up test involving collagen and ADP is used to indicate if the abnormal CT with collagen and EPI was caused by the effects of acetyl sulfosalicylic acid (aspirin) or medications containing inhibitors.
The three broad categories of platelet disorders are "not enough"; "dysfunctional"; and "too many".
- Immune thrombocytopenias (ITP) – formerly known as immune thrombocytopenia purpura and idiopathic thrombocytopenic purpura
- Familial thrombocytopenia
- Thrombotic thrombocytopenic purpura
- HELLP syndrome
- Hemolytic-uremic syndrome
- Drug-induced thrombocytopenic purpura (five known drugs – most problematic is heparin-induced thrombocytopenia (HIT)
- Pregnancy associated
- Neonatal alloimmune associated
- Aplastic anemia
- Transfusion associated
- idiopathic thrombocytopenic purpura
- Gilbert's Syndrome
Altered platelet function
- Disorders of adhesion
- Disorders of activation
- Disorders of aggregation
- Chronic infection
- Chronic inflammation
- Hyposplenism (post-splenectomy)
- Iron deficiency
- Acute blood loss
- Myeloproliferative neoplasms – platelets are both elevated and activated
- Associated with other myeloid neoplasms
Drugs affecting platelets
Some drugs used to treat inflammation have the unwanted side effect of suppressing normal platelet function. These are the non-steroidal anti-inflammatory drugs (NSAIDS). Aspirin irreversibly disrupts platelet function by inhibiting cyclooxygenase-1 (COX1), and hence normal hemostasis. The resulting platelets are unable to produce new cyclooxygenase because they have no DNA. Normal platelet function will not return until the use of aspirin has ceased and enough of the affected platelets have been replaced by new ones, which can take over a week. Ibuprofen, another NSAID, does not have such a long duration effect, with platelet function usually returning within 24 hours, and taking ibuprofen before aspirin prevents the irreversible effects of aspirin.
Drugs that suppress platelet function
These drugs are used to prevent thrombus formation.
Drugs that stimulate platelet production
Therapy with platelets
Platelet transfusion is most frequently used to correct unusually low platelet counts, either to prevent spontaneous bleeding (typically at counts below (10 × 109/L) or in anticipation of medical procedures that will necessarily involve some bleeding. For example, in patients undergoing surgery, a level below 50×109/L is associated with abnormal surgical bleeding, and regional anaesthetic procedures such as epidurals are avoided for levels below 80×109/L. Platelets may also be transfused when the platelet count is normal but the platelets are dysfunctional, such as when an individual is taking aspirin or clopidogrel. Finally, platelets may be transfused as part of a massive transfusion protocol, in which the three major blood components (red blood cells, plasma, and platelets) are transfused to address severe hemorrhage. Platelet transfusion is contraindicated in thrombotic thrombocytopenic purpura (TTP), as it fuels the coagulopathy.
Platelets are either isolated from collected units of whole blood and pooled to make a therapeutic dose, or collected by platelet apheresis: blood is taken from the donor, passed through a device which removes the platelets, and the remainder is returned to the donor in a closed loop. The industry standard is for platelets to be tested for bacteria before transfusion to avoid septic reactions, which can be fatal. Recently the AABB Industry Standards for Blood Banks and Transfusion Services (188.8.131.52) has allowed for use of pathogen reduction technology as an alternative to bacterial screenings in platelets.
Pooled whole-blood platelets, sometimes called “random” platelets, are separated by one of two methods. In the US, a unit of whole blood is placed into a large centrifuge in what is referred to as a “soft spin.” At these settings, the platelets remain suspended in the plasma. The platelet-rich plasma (PRP) is removed from the red cells, then centrifuged at a faster setting to harvest the platelets from the plasma. In other regions of the world, the unit of whole blood is centrifuged using settings that cause the platelets to become suspended in the “buffy coat” layer, which includes the platelets and the white blood cells. The “buffy coat” is isolated in a sterile bag, suspended in a small amount of red blood cells and plasma, then centrifuged again to separate the platelets and plasma from the red and white blood cells. Regardless of the initial method of preparation, multiple donations may be combined into one container using a sterile connection device to manufacture a single product with the desired therapeutic dose.
Apheresis platelets are collected using a mechanical device that draws blood from the donor and centrifuges the collected blood to separate out the platelets and other components to be collected. The remaining blood is returned to the donor. The advantage to this method is that a single donation provides at least one therapeutic dose, as opposed to the multiple donations for whole-blood platelets. This means that a recipient is not exposed to as many different donors and has less risk of transfusion-transmitted disease and other complications. Sometimes a person such as a cancer patient who requires routine transfusions of platelets will receive repeated donations from a specific donor to further minimize the risk. Pathogen reduction of platelets using for example, riboflavin and UV light treatments can also be carried out to reduce the infectious load of pathogens contained in donated blood products, thereby reducing the risk of transmission of transfusion transmitted diseases. Another photochemical treatment process utilizing amotosalen and UVA light has been developed for the inactivation of viruses, bacteria, parasites, and leukocytes that can contaminate blood components intended for transfusion. In addition, apheresis platelets tend to contain fewer contaminating red blood cells because the collection method is more efficient than “soft spin” centrifugation at isolating the desired blood component.
Platelets collected by either method have a very short shelf life, typically five days. This results in frequent problems with short supply, as testing the donations often requires up to a full day. Since there are no effective preservative solutions for platelets, they lose potency quickly and are best when fresh.
Platelets are stored under constant agitation at 20–24 °C (68–75.2 °F). Units can not be refrigerated as this causes platelets to change shape and lose function. Storage at room temperature provides an environment where any bacteria that are introduced to the blood component during the collection process may proliferate and subsequently cause bacteremia in the patient. Regulations are in place in the United States that require products to be tested for the presence of bacterial contamination before transfusion.
Delivery to recipients
Platelets do not need to belong to the same A-B-O blood group as the recipient or be cross-matched to ensure immune compatibility between donor and recipient unless they contain a significant amount of red blood cells (RBCs). The presence of RBCs imparts a reddish-orange color to the product, and is usually associated with whole-blood platelets. An effort is sometimes made to issue type specific platelets, but this is not critical as it is with RBCs.
Prior to issuing platelets to the recipient, they may be irradiated to prevent transfusion-associated graft versus host disease or they may be washed to remove the plasma if indicated.
The change in the recipient's platelet count after transfusion is termed the "increment" and is calculated by subtracting the pre-transfusion platelet count from the post-transfusion platelet count. Many factors affect the increment including the recipient's body size, the number of platelets transfused, and clinical features that may cause premature destruction of the transfused platelets. When recipients fail to demonstrate an adequate post-transfusion increment, this is termed platelet transfusion refractoriness.
Platelets, either apheresis-derived or random-donor, can be processed through a volume reduction process. In this process, the platelets are spun in a centrifuge and the excess plasma is removed, leaving 10 to 100 mL of platelet concentrate. Such volume-reduced platelets are normally transfused only to neonatal and pediatric patients, when a large volume of plasma could overload the child's small circulatory system. The lower volume of plasma also reduces the chances of an adverse transfusion reaction to plasma proteins. Volume reduced platelets have a shelf life of only four hours.
Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the deposition of extracellular matrix; fibroblast growth factor, insulin-like growth factor 1, platelet-derived epidermal growth factor, and vascular endothelial growth factor. Local application of these factors in increased concentrations through Platelet-rich plasma (PRP) is used as an adjunct in wound healing.
- Laki K (Dec 8, 1972). "Our ancient heritage in blood clotting and some of its consequences". Annals of the New York Academy of Sciences. 202: 297–307. doi:10.1111/j.1749-6632.1972.tb16342.x. PMID 4508929.
- Machlus KR; Thon JN; Italiano JE (2014). "Interpreting the developmental dance of the megakaryocyte: A review of the cellular and molecular processes mediating platelet formation". British Journal of Haematology. 165 (2): 227–36. doi:10.1111/bjh.12758. PMID 24499183.
- Jain NC (1975). "A scanning electron microscopic study of platelets of certain animal species". Thrombosis et diathesis haemorrhagica. 33 (3): 501–07. PMID 1154309.
- Michelson, Platelets, 2013, pp. 117–18
- Paulus JM (1975). "Platelet size in man". Blood. 46 (3): 321–36. PMID 1097000.
- Michelson, Platelets, 2013, p. 3
- Yip J; Shen Y; Berndt MC; Andrews RK (2005). "Primary platelet adhesion receptors". IUBMB Life (International Union of Biochemistry and Molecular Biology: Life). 57 (2): 103–08. doi:10.1080/15216540500078962. PMID 16036569.
- Berridge, M.J. (2012) Cell Signalling Biology; doi:10.1042/csb0001011
- Lancet, 1882, ii. 916; Notes of Gulliver's Researches in Anatomy, Physiology, Pathology, and Botany, 1880; Carpenter's Physiology, ed. Power, 9th ed., see Index under 'Gulliver.'
- Godlee, Sir Rickman (1917). Lord Lister. London: Macmillan & Co.
- "Why the Platelets were Discovered", British Journal of Haematology, 12 Mar 2008, Volume 13 Issue s1, pp. 618–37
- Beale LS (1864). "On the Germinal Matter of the Blood, with Remarks upon the Formation of Fibrin". Transactions of the Microscopical Society & Journal. 12: 47–63. doi:10.1111/j.1365-2818.1864.tb01625.x.
- Schultze M (1865). "Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes". Arch Mikrosk Anat. 1 (1): 1–42. doi:10.1007/BF02961404.
- Bizzozero, J. (1882). "Über einen neuen Forrnbestandteil des Blutes und dessen Rolle bei der Thrombose und Blutgerinnung". Arch Pathol Anat Phys Klin Med. 90 (2): 261–332. doi:10.1007/BF01931360.
- Brewer DB (2006). "Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet". Br. J. Haematol. 133 (3): 251–58. doi:10.1111/j.1365-2141.2006.06036.x. PMID 16643426.
- Osler W (1886). "On certain problems in the physiology of the blood corpuscles". The Medical News. 48: 421–25.
- Wright JH (1906). "The Origin and Nature of the Blood Plates". The Boston Medical and Surgical Journal. 154 (23): 643–45. doi:10.1056/NEJM190606071542301.
- Wright JH (1910). "The histogenesis of blood platelets". J Morphology. 21: 263–78. doi:10.1002/jmor.1050210204.
- Furie B; Furie BC (2008). "Mechanisms of thrombus formation". New England Journal of Medicine. 359 (9): 938–49. doi:10.1056/NEJMra0801082. PMID 18753650.
- Girling J.H. (1962). "An automatic platelet counting technique". The Journal of medical laboratory technology. 19: 168–73. PMID 13898919.
- Ross D.W.; Ayscue L.H.; Watson J.; Bentley S.A. (1988). "Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation". American journal of clinical pathology. 90 (3): 262–67. doi:10.1093/ajcp/90.3.262. PMID 3414599.
- Ruocco L.; Del Corso L.; Romanelli A.M.; Deri D.; et al. (2001). "New hematological indices in the healthy elderly". Minerva medica. 92 (2): 69–73. PMID 11323567.
- Lozano M.; Narváez J.; Faúndez A.; Mazzara R.; et al. (1998). "Platelet count and mean platelet volume in the Spanish population". Medicina clinica. 110 (20): 774–77. PMID 9666418.
- Murakawa M; Okamura T; Tsutsumi K; Tanoguchi S; et al. (1992). "Acquired von Willebrand's disease in association with essential thrombocythemia: Regression following treatment". Acta haematologica. 87 (1–2): 83–87. doi:10.1159/000204725. PMID 1585777.
- van Genderen PJ; Leenknegt H; Michiels JJ; Budde U (1996). "Acquired von Willebrand disease in myeloproliferative disorders". Leukemia and Lymphoma. 22 Suppl 1: 79–82. doi:10.3109/10428199609074364. PMID 8951776.
- Michelson, Platelets, 2013, p. 815, Table 39-4
- Harker LA; Roskos LK; Marzec UM; Carter RA; et al. (April 2000). "Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers". Blood. 95 (8): 2514–22. PMID 10753829.
- Mason KD; Carpinelli MR; Fletcher JI; Collinge JE; et al. (2007). "Programmed anuclear cell death delimits platelet life span". Cell. 128 (6): 1173–86. doi:10.1016/j.cell.2007.01.037. PMID 17382885.
- Palmer RM; Ferrige AG; Moncada S (1987). "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor". Nature. 327 (6122): 524–26. doi:10.1038/327524a0. PMID 3495737.
- Jones CI; Barrett NE; Moraes LA; Gibbins JM; et al. (2012). "Endogenous inhibitory mechanisms and the regulation of platelet function". Methods Mol. Biol. 788: 341–66. doi:10.1007/978-1-61779-307-3_23. PMID 22130718.
- Marcus AJ; Broekman MJ; Drosopoulos JH; Olson KE; et al. (2005). "Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection". Seminars in Thrombosis and Hemostasis. 31 (2): 234–46. doi:10.1055/s-2005-869528. PMID 15852226.
- Dubois C; Panicot-Dubois L; Merrill-Skoloff G; Furie B; et al. (May 2006). "Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo". Blood. 107 (10): 3902–06. doi:10.1182/blood-2005-09-3687. PMC . PMID 16455953.
- Matarrese P; Straface E; Palumbo G; Anselmi M; et al. (2009). "Mitochondria regulate platelet metamorphosis induced by opsonized zymosan A—activation and long-term commitment to cell death". FEBS Journal. 276 (3): 845–56. doi:10.1111/j.1742-4658.2008.06829.x. PMID 19143843.
- Behnke O (1970). "The morphology of blood platelet membrane systems". Series haematologica. 3 (4): 3–16. PMID 4107203.
- Phillips DR; Charo IF; Scarborough RM (May 1991). "GPIIb-IIIa: the responsive integrin". Cell. 65 (3): 359–62. doi:10.1016/0092-8674(91)90451-4. PMID 2018971.
- Coller BS; Cheresh DA; Asch E; Seligsohn U (1991). "Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel". Blood. 77 (1): 75–83. PMID 1702031.
- Nguyen, D.T., Orgill D.P., Murphy G.F. (2009). Chapter 4: The Pathophysiologic Basis for Wound Healing and Cutaneous Regeneration. Biomaterials For Treating Skin Loss. Woodhead Publishing (UK/Europe) & CRC Press (US), Cambridge/Boca Raton, pp. 25–57. (ISBN 978-1-4200-9989-8 ISBN 978-1-84569-363-3)
- Movat HZ; Weiser WJ; Glynn MF; Mustard JF (1965). "Platelet phagocytosis and aggregation". J. Cell Biol. 27 (3): 531–43. doi:10.1083/jcb.27.3.531. PMC . PMID 4957257.
- Bouchard BA; Mann KG; Butenas S (August 2010). "No evidence for tissue factor on platelets". Blood. 116 (5): 854–55. doi:10.1182/blood-2010-05-285627. PMC . PMID 20688968.
- Ahmad SS; Rawala-Sheikh R; Walsh PN (1992). "Components and assembly of the factor X activating complex". Semin. Thromb. Hemost. 18 (3): 311–23. doi:10.1055/s-2007-1002570. PMID 1455249.
- "Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype.". Blood. 123: 1250–60. Feb 2014. doi:10.1182/blood-2013-05-501924. PMID 24297866.
- Weyrich AS; Zimmerman GA (2004). "Platelets: signaling cells in the immune continuum". Trends Immunol. 25 (9): 489–95. doi:10.1016/j.it.2004.07.003. PMID 15324742.
- Wagner DD; Burger PC (2003). "Platelets in inflammation and thrombosis". Arterioscler. Thromb. Vasc. Biol. 23 (12): 2131–37. doi:10.1161/01.ATV.0000095974.95122.EC. PMID 14500287.
- Diacovo TG; Puri KD; Warnock RA; Springer TA; et al. (1996). "Platelet-mediated lymphocyte delivery to high endothelial venules". Science. 273 (5272): 252–55. doi:10.1126/science.273.5272.252. PMID 8662511.
- Iannacone M; Sitia G; Isogawa M; Marchese P; et al. (2005). "Platelets mediate cytotoxic T lymphocyte-induced liver damage". Nat. Med. 11 (11): 1167–69. doi:10.1038/nm1317. PMC . PMID 16258538.
- Schmaier AA; Stalker TJ; Runge JJ; Lee D; et al. (September 2011). "Occlusive thrombi arise in mammals but not birds in response to arterial injury: evolutionary insight into human cardiovascular disease". Blood. 118 (13): 3661–69. doi:10.1182/blood-2011-02-338244. PMC . PMID 21816834.
- Belamarich FA; Shepro D; Kien M (November 1968). "ADP is not involved in thrombin-induced aggregation of thrombocytes of a non-mammalian vertebrate". Nature. 220 (5166): 509–10. doi:10.1038/220509a0. PMID 5686175.
- Duke WW (1910). "The relation of blood platelets to hemorrhagic disease". JAMA. 55: 1185–92. doi:10.1001/jama.1910.04330140029009.
- Michelson, Platelets, 2013, p. vii
- Geddis, AE (Feb 2013). "Inherited thrombocytopenias: an approach to diagnosis and management". International journal of laboratory hematology. 35 (1): 14–25. doi:10.1111/j.1751-553x.2012.01454.x. PMID 22846067.
- Cure MC, Cure E, Kirbas A, Cicek AC, Yuce S (2013). "The effects of Gilbert's syndrome on the mean platelet volume and other hematological parameters". Blood Coagul. Fibrinolysis. 24: 484–88. doi:10.1097/MBC.0b013e32835e4230. PMID 23348429.
- Kornerup KN; Page CP (2007). "The role of platelets in the pathophysiology of asthma". Platelets. 18 (5): 319–28. doi:10.1080/09537100701230436. PMID 17654302.
- Laidlaw TM; Kidder MS; Bhattacharyya N; Xing W; et al. (2012). "Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes". Blood. 119 (16): 3790–98. doi:10.1182/blood-2011-10-384826. PMC . PMID 22262771.
- Erpenbeck L; Schön MP (2010). "Deadly allies: the fatal interplay between platelets and metastasizing cancer cells". Blood. 115 (17): 3427–36. doi:10.1182/blood-2009-10-247296. PMC . PMID 20194899.
- Pleass RJ (2009). "Platelet power: sticky problems for sticky parasites?". Trends Parasitol. 25 (7): 296–99. doi:10.1016/j.pt.2009.04.002. PMC . PMID 19539528.
- "Platelet Function after Taking Ibuprofen for 1 Week". Annals of Internal Medicine. 142 (7): I54. 2005. doi:10.7326/0003-4819-142-7-200504050-00004. PMID 15809457.
- Rao GH; Johnson GG; Reddy KR; White JG (1983). "Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin". Arteriosclerosis. 3 (4): 383–88. doi:10.1161/01.ATV.3.4.383. PMID 6411052.
- van Veen JJ; Nokes TJ; Makris M (2010). "The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals". Br. J. Haematol. 148 (1): 15–25. doi:10.1111/j.1365-2141.2009.07899.x. PMID 19775301.
- Roback, J.; Grossman, B.; Harris, T.; Hillyer, C., eds. (2011). Technical Manual (17th ed.). Bethesda MD: AABB. p. 580. ISBN 978-1-56395-315-6.
- American Association of Blood Banks (2003). "184.108.40.206". Standards for Blood Banks and Transfusion Services (22nd ed.). Bethesda MD: AABB.
- Högman CF (1992). "New trends in the preparation and storage of platelets". Transfusion. 32 (1): 3–6. doi:10.1046/j.1537-2995.1992.32192116428.x. PMID 1731433.
- Ruane PH; Edrich R; Gampp D; Keil SD; et al. (2004). "Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light". Transfusion. 44 (6): 877–85. doi:10.1111/j.1537-2995.2004.03355.x. PMID 15157255.
- Perez-Pujol S; Tonda R; Lozano M; Fuste B; et al. (2005). "Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates". Transfusion. 45 (6): 911–19. doi:10.1111/j.1537-2995.2005.04350.x. PMID 15934989.
- Prowse CV (2013). "Component pathogen inactivation: A critical review". Vox Sanguinis. 104 (3): 183–99. doi:10.1111/j.1423-0410.2012.01662.x.
- AABB (2009). Standards for Blood Banks and Transfusion Services (26th ed.). Bethesda MD: AABB.
- Schoenfeld H; Spies C; Jakob C (2006). "Volume-reduced platelet concentrates". Curr. Hematol. Rep. 5 (1): 82–88. PMID 16537051.
- CBBS: Washed and volume-reduced Plateletpheresis units. Cbbsweb.org (2001-10-25). Retrieved on 2011-11-14.
- Gawaz M; Vogel S (October 2013). "Platelets in tissue repair: control of apoptosis and interactions with regenerative cells". Blood. 122 (15): 2550–54. doi:10.1182/blood-2013-05-468694. PMID 23963043.
- Michelson, Alan D. (2013). Platelets (3rd ed.). Academic. ISBN 0-12-387837-3. – 1351 pages; 60,000 references. Excerpts free online.
- Media related to platelets at Wikimedia Commons